Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

norovirus

- PMLiVE

Free Live Webinar – Uniting Communities for Rare Disease Clinical Trial Success

Join this live webinar focusing on patient recruitment and retention in rare disease trials.

Innovative Trials

- PMLiVE

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

With rapid growth comes growing pains...

Impetus Digital

- PMLiVE

Takeda’s fruquintinib recommended by CHMP for metastatic colorectal cancer

Approximately 520,000 new cases of colorectal cancer were diagnosed in Europe in 2020

- PMLiVE

Takeda’s subcutaneous Entyvio approved by FDA as Crohn’s disease maintenance therapy

Inflammatory bowel disease affects around ten million people worldwide

- PMLiVE

Takeda gains rights to Kumquat’s immune-oncology programme in deal worth over $1.2bn

The selected candidate can be developed as a monotherapy, combination therapy or both

- PMLiVE

FDA establishes new CDER centre focused on promoting clinical trial innovation

The C3TI will give internal and external parties easier access to information on clinical trial innovation

- PMLiVE

Takeda’s Takhzyro granted MHRA approval for younger hereditary angioedema patients

The rare genetic disorder is estimated to affect one in every 50,000 people

- PMLiVE

Takeda’s HyQvia receives MHRA approval for rare neurological disorder CIDP

The therapy offers patients with CIDP a typical dosing interval of four weeks

- PMLiVE

Takeda’s Iclusig combination granted FDA accelerated approval for rare form of leukaemia

The drug is now the first targeted therapy approved as a frontline treatment for Ph-positive ALL

- PMLiVE

Innovative Trials recognised at the PMEA Awards 2023 Gala Dinner

Global patient recruitment Innovative Trials took part of the PMEA Awards gala dinner alongside the best players in the pharmaceutical industry.

Innovative Trials

- PMLiVE

Innovative Trials launches the Retention Patch Program

Innovative Trials has unveiled a new partnership with the non-profit Oliver Patch Project to boost retention in pediatric studies.

Innovative Trials

HCP icons in Cuttsy+Cuttsy branded shapes

Clinical trial considerations: Why supporting HCPs matters…

When HCPs have the necessary information, they can more easily communicate it to patients using simplified language and a confident, calm tone.

Cuttsy + Cuttsy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links